Supply Chain Intelligence

Corvus Pharmaceuticals, Inc. Supply Chain

CRVS supply chain intelligence for Corvus Pharmaceuticals, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

CRVS ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

4Suppliers
0Customers
3Debt Items
20Related Chains

Corvus Pharmaceuticals, Inc. Suppliers

TickerNameConfidenceEvidence
ANGEL-PHARMACEUTICALS ANGEL-PHARMACEUTICALS 90% The Company’s ownership interest in Angel Pharmaceuticals was approximately 49.7 %, excluding 7 % of Angel Pharmaceuticals’ equity reserved for issuance under the Angel Pharmaceuticals Employee Stock…
JEFFERIES-LLC JEFFERIES-LLC 90% Jefferies is not required to sell any specific number or dollar amount of shares of the Common Stock, but has agreed, subject to the terms and conditions of the Amended Sales Agreement, to use its co…
SNYNF Sanofi 72% zed clinical trial in order to prioritize the development of our other two lead product candidates. Angel Pharmaceuticals is continuing the development of mupadolimab in China. Manufacturing We do no…
SNYNF Sanofi 72% Reciprocal relationship from SNYNF graph: Reciprocal relationship from CRVS graph: zed clinical trial in order to prioritize the development of our other two lead product candidates. Angel Pharmaceut…

Corvus Pharmaceuticals, Inc. Customers

No clients on recordNo downstream customers found in our database for Corvus Pharmaceuticals, Inc..

Corvus Pharmaceuticals, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
CRVS-DEBT-8874 Warrants outstanding: 8934000 90% xbrl warrant detail from xbrl 2025-12-31.
CRVS-DEBT Debt stack $834,000 90% Market cache reports total debt of $834,000.
CRVS-DEBT-8875 Xbrl Convertible 90% xbrl convertible detail from xbrl 2025-12-31.

Corvus Pharmaceuticals, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Corvus Pharmaceuticals, Inc..

Corvus Pharmaceuticals, Inc. Ownership

HolderNameConfidenceEvidence
CRVS-OWNER-ORBIMED-ADVISORS-LLC ORBIMED ADVISORS LLC 90% 13F overlay lists ORBIMED ADVISORS LLC as top holder; 167 tracked holders.

Corvus Pharmaceuticals, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
SNYNF Sanofi 100.00 1 ['supplier']
ALXO ALX Oncology Holdings Inc. 50.00 2
DBVTF DBV TECHNOLOGIES 50.00 2
CTMX CytomX Therapeutics, Inc. 50.00 2
ANL Adlai Nortye Ltd. 50.00 2
ANRO Alto Neuroscience, Inc. 50.00 2
BIOA BioAge Labs, Inc. 50.00 2
CYTK Cytokinetics, Incorporated 50.00 2
CBIO Crescent Biopharma, Inc. 50.00 2
RXRX Recursion Pharmaceuticals, Inc. 50.00 2
CCEP Coca-Cola Europacific Partners PLC 50.00 2
DSGN Design Therapeutics, Inc. 50.00 2
AZN AstraZeneca PLC 50.00 2
CLDX Celldex Therapeutics, Inc. 50.00 2
CYTOF Altamira Therapeutics Ltd. 50.00 2
EDIT Editas Medicine, Inc. 50.00 2
FULC Fulcrum Therapeutics, Inc. 50.00 2
LGND Ligand Pharmaceuticals Incorporated 50.00 2
ATOS Atossa Therapeutics, Inc. 50.00 2
WHWK Whitehawk Therapeutics, Inc. 50.00 2
View CRVS supply chain intel →

Explore the full interactive supply chain map for Corvus Pharmaceuticals, Inc..

Open CRVS supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map